Choreo LLC Boosts Stock Holdings in AbbVie Inc. $ABBV

Choreo LLC increased its holdings in AbbVie Inc. (NYSE:ABBV) by 0.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 108,650 shares of the company’s stock after buying an additional 487 shares during the period. Choreo LLC’s holdings in AbbVie were worth $20,168,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of ABBV. TD Capital Management LLC lifted its position in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after acquiring an additional 58 shares during the last quarter. Marshall & Sullivan Inc. WA purchased a new position in AbbVie in the 2nd quarter worth $25,000. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie during the second quarter worth about $28,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie during the 2nd quarter valued at approximately $36,000. Finally, Bear Mountain Capital Inc. boosted its holdings in AbbVie by 480.6% in the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after purchasing an additional 173 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

NYSE:ABBV opened at $231.83 on Wednesday. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The company has a market cap of $409.74 billion, a price-to-earnings ratio of 110.40, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The company has a fifty day simple moving average of $227.36 and a two-hundred day simple moving average of $206.12.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same quarter last year, the company earned $3.00 EPS. AbbVie’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.0%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is currently 524.24%.

Wall Street Analyst Weigh In

ABBV has been the topic of several recent research reports. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the stock an “overweight” rating in a research report on Thursday, October 9th. BMO Capital Markets lifted their price objective on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, September 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a research report on Tuesday, November 4th. Finally, Wells Fargo & Company upped their price objective on shares of AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $241.85.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.